



## Announcement

23.10.2012

### Report on Extraordinary General Meeting in NeuroSearch A/S

At the company's Extraordinary General Meeting today, the sale of Huntexil® to Teva Pharmaceutical Industries Ltd. through the fully owned affiliate Ivax International GmbH was approved by the general meeting.

The obtained approval from NeuroSearch shareholders is one of several conditions for the sale of Huntexil®. NeuroSearch will inform the market as soon as the transaction with Teva has been fully completed.

René Schneider  
CEO

#### Contact person:

René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097

#### About NeuroSearch

NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and orodopidine and seridopidine, both of which have completed phase I studies as well as tesofensine for anti-obesity, which is currently in phase II.

